Using LIS1 missense mutations to probe dynein regulatory mechanisms - SUMMARY: It is becoming clear that genes associated with different neurological diseases are shared
across disorders and converge on common functional pathways. For example, pathways that control the
microtubule motor cytoplasmic dynein 1 (hereafter referred to as “dynein”) are perturbed in multiple
disorders from cortical malformations to ALS and other degenerative diseases [1]. This motor is
indispensable for a wide range of cellular processes in the developing and mature nervous system [2].
Our group is interested in the dynein regulatory protein, LIS1. As a vital dynein regulator, it is surprising
that PAFAH1B1 mutations have not been found in other neurological diseases. We are currently
studying a novel LIS1 missense mutation (K351R) in a boy with Autism Spectrum Disorder (ASD),
supporting the possibility that some LIS1 mutations can lead to less severe disease. Most, if not all, LIS1
roles are related to dynein regulation. Around 20 genes encoding LIS1-interacting or dynein regulatory
proteins that have potential autism spectrum disorder (ASD)-linked mutations, so perturbations in
dynein regulation could predispose to ASD. There are other missense mutations that could lead to
partially functional proteins in several online databases. In this R21 exploratory project we will test the
hypothesis that individual LIS1 missense mutations will disrupt specific LIS1 interactions, thereby
differentially regulating dynein and impacting disease severity. We will determine how each mutation
impacts critical LIS1 interactions, and how they impact LIS1’s ability to regulate dynein.
This study will be the first to systematically dissect the impact of LIS1 missense mutations in different
domains of the protein on dynein function, and to correlate changes in dynein function with disease
severity. As neurons are uniquely sensitive to reduced LIS1 expression they might be negatively
impacted even by small changes in LIS1 that subtly alter dynein function. Because LIS1 is critical in both
the developing and adult nervous system, our studies could provide a springboard for understanding
dynein deregulation across a wide range of neurological disorders, including ASD and later onset
disorders such as Alzheimer’s Disease and Amyotrophic Lateral Sclerosis.